Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study

Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Ph...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nader ND, Hamishehkar H, Naghizadeh A, Shadvar K, Iranpour A, Sanaie S, Chang F, Mahmoodpoor A
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
Acceso en línea:https://doaj.org/article/9b18ed16c0024a69a5b5cd85888f4101
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:9b18ed16c0024a69a5b5cd85888f4101
record_format dspace
spelling oai:doaj.org-article:9b18ed16c0024a69a5b5cd85888f41012021-12-02T05:44:05ZEffect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study1178-7007https://doaj.org/article/9b18ed16c0024a69a5b5cd85888f41012020-03-01T00:00:00Zhttps://www.dovepress.com/effect-of-adding-insulin-glargine-on-glycemic-control-in-critically-il-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Anesthesiology and Critical Care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Al Garhoud Private Hospital, Dubai, United Arab Emirates; 5Neurosiences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Ata MahmoodpoorAnesthesiology, Tabriz University of Medical Sciences, School of Medicine, Tabriz, IranEmail amahmoodpoor@yahoo.comObjective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).Methods: A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140– 180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann–Whitney U test.Results: Average daily glucose level was significantly less in the glargine group than controls (P< 0.0001), while there was no difference in daily variance in blood glucose between the two groups. The duration of glucose concentrations being within the target range was identical between the glargine and control groups (16.6± 4.9 vs 16.4± 4.6 hours/day, P=0.844) during the 7 days of admission. The frequency of hypoglycemia was greater in the glargine group and total duration of hyperglycemia (> 180 mg/dL) much longer among controls (P< 0.001). Similar mortality rates were observed in both groups, while ICU length of stay was 2 days shorter in the glargine group.Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.Keywords: critically ill patients, dysglycemia, hyperglycemia, insulin glargineNader NDHamishehkar HNaghizadeh AShadvar KIranpour ASanaie SChang FMahmoodpoor ADove Medical Pressarticlecritically ill patientsdysglycemiahyperglycemiainsulin glargineSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 671-678 (2020)
institution DOAJ
collection DOAJ
language EN
topic critically ill patients
dysglycemia
hyperglycemia
insulin glargine
Specialties of internal medicine
RC581-951
spellingShingle critically ill patients
dysglycemia
hyperglycemia
insulin glargine
Specialties of internal medicine
RC581-951
Nader ND
Hamishehkar H
Naghizadeh A
Shadvar K
Iranpour A
Sanaie S
Chang F
Mahmoodpoor A
Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
description Nader D Nader,1 Hadi Hamishehkar,2 Abdolreza Naghizadeh,3 Kamran Shadvar,3 Afshin Iranpour,4 Sarvin Sanaie,5 Francis Chang,1 Ata Mahmoodpoor3 1State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 2Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Anesthesiology and Critical Care, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Al Garhoud Private Hospital, Dubai, United Arab Emirates; 5Neurosiences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Ata MahmoodpoorAnesthesiology, Tabriz University of Medical Sciences, School of Medicine, Tabriz, IranEmail amahmoodpoor@yahoo.comObjective: We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).Methods: A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140– 180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann–Whitney U test.Results: Average daily glucose level was significantly less in the glargine group than controls (P< 0.0001), while there was no difference in daily variance in blood glucose between the two groups. The duration of glucose concentrations being within the target range was identical between the glargine and control groups (16.6± 4.9 vs 16.4± 4.6 hours/day, P=0.844) during the 7 days of admission. The frequency of hypoglycemia was greater in the glargine group and total duration of hyperglycemia (> 180 mg/dL) much longer among controls (P< 0.001). Similar mortality rates were observed in both groups, while ICU length of stay was 2 days shorter in the glargine group.Conclusion: Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.Keywords: critically ill patients, dysglycemia, hyperglycemia, insulin glargine
format article
author Nader ND
Hamishehkar H
Naghizadeh A
Shadvar K
Iranpour A
Sanaie S
Chang F
Mahmoodpoor A
author_facet Nader ND
Hamishehkar H
Naghizadeh A
Shadvar K
Iranpour A
Sanaie S
Chang F
Mahmoodpoor A
author_sort Nader ND
title Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
title_short Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
title_full Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
title_fullStr Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
title_full_unstemmed Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
title_sort effect of adding insulin glargine on glycemic control in critically ill patients admitted to intensive care units: a prospective randomized controlled study
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/9b18ed16c0024a69a5b5cd85888f4101
work_keys_str_mv AT nadernd effectofaddinginsulinglargineonglycemiccontrolincriticallyillpatientsadmittedtointensivecareunitsaprospectiverandomizedcontrolledstudy
AT hamishehkarh effectofaddinginsulinglargineonglycemiccontrolincriticallyillpatientsadmittedtointensivecareunitsaprospectiverandomizedcontrolledstudy
AT naghizadeha effectofaddinginsulinglargineonglycemiccontrolincriticallyillpatientsadmittedtointensivecareunitsaprospectiverandomizedcontrolledstudy
AT shadvark effectofaddinginsulinglargineonglycemiccontrolincriticallyillpatientsadmittedtointensivecareunitsaprospectiverandomizedcontrolledstudy
AT iranpoura effectofaddinginsulinglargineonglycemiccontrolincriticallyillpatientsadmittedtointensivecareunitsaprospectiverandomizedcontrolledstudy
AT sanaies effectofaddinginsulinglargineonglycemiccontrolincriticallyillpatientsadmittedtointensivecareunitsaprospectiverandomizedcontrolledstudy
AT changf effectofaddinginsulinglargineonglycemiccontrolincriticallyillpatientsadmittedtointensivecareunitsaprospectiverandomizedcontrolledstudy
AT mahmoodpoora effectofaddinginsulinglargineonglycemiccontrolincriticallyillpatientsadmittedtointensivecareunitsaprospectiverandomizedcontrolledstudy
_version_ 1718400247372185600